HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

P A Palmer Selected Research

laniquidar (R101933)

5/2002Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.
4/2000The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


P A Palmer Research Topics

Disease

3Neoplasms (Cancer)
11/2006 - 01/2002
2Diarrhea
11/2006 - 10/2004
2Neutropenia
11/2006 - 10/2004
1Thrombocytopenia (Thrombopenia)
10/2004
1Exanthema (Rash)
10/2004
1Colorectal Neoplasms (Colorectal Cancer)
10/2004
1Carcinoma (Carcinomatosis)
06/2002
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2002
1Sleepiness
05/2002
1Fever (Fevers)
04/2000
1Mucositis
04/2000

Drug/Important Bio-Agent (IBA)

4tipifarnib (R115777)IBA
11/2006 - 01/2002
3TransferasesIBA
11/2006 - 06/2002
2Proteins (Proteins, Gene)FDA Link
11/2006 - 06/2002
2laniquidar (R101933)IBA
05/2002 - 04/2000
1Capecitabine (Xeloda)FDA Link
11/2006
1Biological ProductsIBA
11/2006
1Carcinoembryonic AntigenIBA
06/2002
1Codon (Codons)IBA
06/2002
1PlatinumIBA
06/2002
1Tumor Biomarkers (Tumor Markers)IBA
06/2002
1TabletsIBA
01/2002
1Capsules (Microcapsules)IBA
01/2002
1Antineoplastic Agents (Antineoplastics)IBA
01/2002
1Docetaxel (Taxotere)FDA Link
04/2000

Therapy/Procedure

1Oral Administration
06/2002